











































Ultrasound is a poor predictor of early or overt liver or spleen
metastasis in dogs with high-risk mast cell tumours.
Citation for published version:
Pecceu, E, Serra, JC, Handel, I, Piccinelli, C, Milne, E & Lawrence, J 2020, 'Ultrasound is a poor predictor
of early or overt liver or spleen metastasis in dogs with high-risk mast cell tumours.', Veterinary and
Comparative Oncology. https://doi.org/10.1111/vco.12563
Digital Object Identifier (DOI):
10.1111/vco.12563
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Veterinary and Comparative Oncology
Publisher Rights Statement:
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
OR I G I N A L A R T I C L E
Ultrasound is a poor predictor of early or overt liver or spleen
metastasis in dogs with high-risk mast cell tumours
Evi Pecceu | Juan Carlos Serra Varela | Ian Handel | Chiara Piccinelli |
Elspeth Milne | Jessica Lawrence
Royal (Dick) School of Veterinary Studies &
Roslin Institute, University of Edinburgh,
Roslin, UK
Correspondence
Evi Pecceu, Royal (Dick) School of Veterinary
Studies & Roslin Institute, University of
Edinburgh, Roslin, EH25 9RG, UK.
Email: evi.pecceu@gmail.com
Present address:
Dr Jessica Lawrence, College of Veterinary
Medicine, University of Minnesota, St Paul,
MN 55108.
Abstract
Conflicting evidence exists regarding the importance of routine abdominal ultrasound
(US) with hepatic and splenic fine needle aspiration (FNA) cytology during staging of
canine mast cell tumours (MCT). The objective of this study was to correlate ultrasono-
graphic and cytologic findings in dogs with strictly defined high-risk MCTs and to deter-
mine the influence on outcome. Our hypothesis was that US poorly predicts visceral
metastasis in high-risk MCTs and that early metastasis is associated with improved out-
come when compared to overt metastasis. US of liver and spleen correlated to cytologic
results, categorized as no metastasis, early metastasis or overt metastasis. Of 82 dogs
prospectively enrolled, 18% had early visceral metastasis and 7% had overt metastasis
on cytology; 67% with visceral metastasis had regional LN metastasis. US was a poor
predictor of metastasis with sensitivity, specificity, positive predictive value and negative
predictive value for the spleen of 67%, 68%, 21% and 94%, respectively and for the liver
of 29%, 93%, 56% and 82%, respectively. Median time to progression (TTP) for dogs
with no metastasis, early metastasis and overt metastasis was not reached, 305 and
69 days, respectively (P < .001). Median survival time (MST) for the 3 groups were not
reached, 322 and 81 days, respectively (P < .001). High Patnaik or Kiupel grade, early
metastasis, overt metastasis and adequate local control were significantly associated
with outcome. Early visceral metastasis was associated with poorer outcome compared
to dogs without metastasis, however, a subset of dogs experienced long-term control.
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1 | INTRODUCTION
Canine mast cell tumours (MCTs) represent 16%-21% of cutaneous
tumours and are the second most common malignancy in the UK.1-5
MCTs display variable clinical behaviour ranging from a localized mass
to aggressive disease with distant metastasis. Consistent negative
prognostic indicators include tumour recurrence, metastasis, rapid
growth, ulceration, grade III Patnaik, high grade Kiupel, high risk loca-
tions (mucocutaneous sites, prepuce and scrotum) and high mitotic
count (MC).6-32 Prior to determining treatment options, staging is rec-
ommended for tumours considered at high-risk for metastasis. Full
staging includes haematology/biochemistry, regional lymph node
(LN) fine needle aspiration (FNA) cytology, thoracic radiographs, and
abdominal ultrasound (US) with hepatic and splenic FNA cytology.33
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While current literature provides information on dogs with distant
metastasis, precise staging data is often lacking clear documentation
of whether visceral metastasis was classified on the basis of cytologic
findings or US appearance alone.11,18,30,34-38 When normal on US,
liver and spleen may not be aspirated and several studies include
patients without full staging.12,19,39-43
The utility of US to predict cytologic findings is controversial. One
study demonstrated that sensitivity of US to detect liver and spleen
metastasis was 0% and 43%, respectively.44 Another study suggested a
sensitivity of 71% for both liver and spleen.45 A recent study reported
that all dogs with cytologic confirmation of metastasis had abnormal
ultrasound findings.27 Routine aspiration of the liver and spleen is also
debatable. The presence of mast cells is not definitively diagnostic for
metastasis as they can be present in healthy dogs and dogs with non-
neoplastic conditions.28,46-52 Cytologic guidelines for the designation of
visceral MCT metastasis have been described.27 Using these criteria,
dogs with distant metastasis were shown to have a poor outcome with
a median survival time (MST) of 34 and 100 days compared to >733
and 291 days, respectively, for dogs without metastasis.27,44 In the
authors' experience, some dogs have cytologic findings that do not fit
the criteria for overtly positive metastasis. These dogs have FNA results
characterized by, a mild subjective increase in numbers of mast cells of
normal morphology, not associated with connective tissue elements,
where early metastasis cannot be ruled out. This cytologic finding
therefore creates a challenge when determining treatment decisions.
The overall value of routine US and cytology of the liver and
spleen in dogs with MCTs is unclear, because dogs with low-to-
intermediate grade tumours without negative prognostic factors have
a favourable prognosis after surgery, even following incomplete or
narrow margins.20,50,53,54 However, routine hepatic and splenic cyto-
logic assessment is probably useful for dogs at high-risk for visceral
metastasis.27,44 Cytologic evidence of early metastasis may be prog-
nostic and alter treatment decisions. The objective of this study was
to prospectively correlate US and cytologic findings in dogs with high-
risk MCTs, and to determine the outcome of dogs with early metasta-
sis compared to dogs without metastasis and those with overt visceral
metastasis. The hypothesis was that US is poorly predictive of hepatic
or splenic metastasis when selecting for dogs at high-risk for MCT
metastasis, and that dogs with cytologic evidence of early metastasis
have improved outcomes compared to dogs with overt metastasis.
2 | METHODS
2.1 | Dogs
Dogs that presented to a referral oncology service between March
2013 and May 2017 for staging of high-risk MCTs diagnosed on
cytology and/or histopathology were prospectively enrolled. The
study was conducted following approval by the University veterinary
ethical review committee. Written owner consent was obtained for all
dogs. A subset of the cases had previously been published in a study
on escalating vinblastine protocol in dogs with MCTs.55 Dogs were
included if they had negative prognostic indicators consistent with
biologically aggressive behaviour and if US and FNA cytology of liver
and spleen were scheduled to be performed as part of full staging.
Strict criteria for designation of “high risk” included the following neg-
ative prognostic indicators: grade III Patnaik and/or high grade Kiupel),
mitotic count >5, LN metastasis, recurrent disease, recent rapid
growth and ulceration, and high-risk location (mucocutaneous, prepu-
tial, scrotal or visceral).6-32 Rapid growth was defined as volume
increase of >200% in the 30 days prior to clinical exam.
LN evaluation on cytology was performed using previously publi-
shed guidelines and histopathological evaluation from 2015 onwards
was performed according to the classification published in 2014.15,32
Both HN2 and HN3 were documented as metastatic for the current
study as these had been reported to be associated with outcome.
2.2 | Staging
Staging included physical examination with MCT measurement where
present, haematology, serum biochemistry, regional LN evaluation and
FNA cytology, three view thoracic radiographs, and abdominal US
with FNA cytology of liver and spleen. All palpable regional LNs were
sampled; non-palpable LNs were sampled where feasible with US-
guidance. If surgical removal was elected, the regional LN was excised
and submitted for histopathology. US with FNA of the liver and spleen
was performed by board-certified specialists in diagnostic imaging.
Sedation was used to facilitate imaging and FNA. Liver and spleen
appearance on US was characterized as nodules, masses, altered
echogenicity, enlargement or normal appearance. FNA of the liver/
spleen was attempted regardless of the US findings and when abnor-
malities were present, both abnormal and normal regions were aspi-
rated. FNA was performed using a 23-gauge needle attached to a
5 mL syringe without any active aspiration at the time of sampling to
avoid blood contamination, based on radiologist preference. Slides
were stained with May-Grünwald Giemsa and cytologic evaluation
was performed by one of two board-certified pathologists. Prior to
sampling the liver and spleen, manual platelet counts were assessed
and congenital coagulopathies were ruled out based on clinical his-
tory. If there was a history of liver disease, partial thromboplastin time
and activated partial thromboplastin time were assessed in house.
2.3 | Cytologic interpretation of liver and spleen
Dogs were assigned to 3 groups based on a modification of previous
recommendations and included: no metastasis, early metastasis and
overt metastasis.27 Criteria used can be seen in Table 1.
2.4 | Data collection
Data collected for all dogs included age, sex, breed, weight, date of
diagnosis, previous and/or concurrent MCTs, tumour size, grade
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(Patnaik and Kiupel), localized clinical signs, systemic clinical signs, LN
assessment, US appearance of liver and spleen, cytology results of
liver and spleen, duration from diagnosis to staging, treatment (sys-
temic treatment, surgery, radiation therapy), surgical margins, whether
adequate local control was achieved, time to progression or metasta-
sis (TTP), survival time (ST), and cause of death. Adequate local control
at our institution at the time of prospective study design was defined
as surgery with wide margins (≥ 3 mm for grade I-II Patnaik or low
grade Kiupel, ≥5 mm for grade III Patnaik or high-grade Kiupel) or
incomplete or narrow surgical margins followed by definitive-intent
radiation therapy (RT) of the primary tumour site and regional LN bed
where feasible.54,56-59 Chemotherapy with escalating vinblastine and
prednisolone was recommended for all dogs diagnosed with MCT at
high-risk for metastasis following local control.55 TTP was defined as
time from date of diagnosis to the date of progression of the primary
tumour, local recurrence or development of metastasis. The develop-
ment of de novo MCTs was not documented as progression unless
greater than five MCTs appeared rapidly (within 14 days) in the face
of therapy, in which case skin metastasis was presumed. Survival time
was documented as time from date of diagnosis to date of death. Rec-
ommended follow-up included recheck examination once every
3 months for 18 months, followed by once every 6 months for
18 months, followed by yearly revisits. At the time of recheck, physi-
cal examination, regional LN measurement +/− FNA cytology, and US
and with liver/spleen FNA were recommended.
2.5 | Statistical analysis
Statistical analyses were performed using the R Statistical System
(R Core Team 2015).60 Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were calculated to evaluate
US in relation to cytology results. TTP and MST were calculated using
Kaplan-Meier curves and 95% confidence intervals. For TTP, dogs
were censored if they were alive without evidence of progressive dis-
ease at the time of last follow-up. For MST, dogs were censored if
they were alive at the time of last follow-up regardless of the status
of disease progression and if they died due to MCT-unrelated causes.
Cox-proportional hazards regression model was used to determine if
high-risk location, MCT recurrence, rapid growth and ulceration, grade
III Patnaik, high-grade Kiupel), high MC, LN metastasis, early hepatic
or splenic metastasis, overt hepatic or splenic metastasis, surgery,
adequate loco-regional control or chemotherapy had a significant
impact on outcome. The proportional hazard assumption was
assessed by graphical examination of the Schoenfeld residuals for
each variable against time and a null hypothesis test that there is not
a time dependent trend in these residuals (using the cox.zph function
in the R survival package). Multivariable analysis was performed to
evaluate for factors related to outcome within groups and between
groups. For this analysis, variables were grouped into primary tumour
characteristics (rapid growth and ulceration, high risk location, recur-
rence, grade III Patnaik or Kiupel high grade, high MC), metastasis sta-
tus (no metastasis, LN metastasis, early liver or spleen metastasis,
overt liver or spleen metastasis) and treatment variables (surgery of
the primary tumour +/− regional LN, adequate local control, chemo-
therapy). A P-value of <.05 was considered statistically significant.
3 | RESULTS
Eighty-two dogs met the inclusion criteria and were enrolled. One dog
previously received targeted therapy with masitinib for a MCT, how-
ever, this medication was discontinued 1 month prior to referral
because of the development of a metastatic MCT. None of the other
dogs had received any chemotherapy or targeted therapy prior to
referral. Represented breeds and clinical characteristics and outcome
are summarized in Tables 2 and 3, respectively. Of note, rapid growth
and ulceration occurred simultaneously in dogs affected. Two cases
presented with clinical signs at time of diagnosis. One dog had a rap-
idly growing, bruised and ulcerated, 8.0 cm diameter mass in the ingui-
nal area with no evidence of LN or visceral metastasis. Clinical signs
included hyporexia and lethargy. The other dog had a 4.5 cm ulcer-
ated rapidly growing mass on the pinna (high grade Patnaik and Kiupel
with a high MC), with LN and visceral metastasis at time of diagnosis
and clinical signs included diarrhoea with frank blood, lethargy and
weakness. Sixty-one dogs (74%) presented with cutaneous MCT,
12 dogs (15%) presented with subcutaneous MCT, 8 dogs (10%) pres-
ented with mucocutaneous MCT and 1 dog (1%) presented with vis-
ceral MCT (Table 4). Haematology and serum biochemistry were
performed in all dogs. Thoracic radiography was performed in 74 cases
(90%) and none revealed lymphadenopathy or pulmonary metastasis.
All regional LNs were assessed (for MCTs on the caudal half of the
TABLE 1 Criteria used to assign metastasis status on cytology of the liver and spleen
Liver Spleen
No metastasis One or less individualized well-granulated
mast cells per 100 hepatocytes
No or rare and scattered individualized
well-granulated mast cells
Early metastasis 2-4 individualized well-granulated mast cells
per 100 hepatocytes
Subjective mildly increased number of
individualized well-granulated mast cells
not associated with connective tissue
elements
Overt metastasis Clusters or ≥5 well differentiated mast cells
per 100 hepatocytes
Clusters or subjective large number of
individualized well-granulated mast cells
or cells with atypical morphology
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body inguinal and medial iliac LNs, for MCTs on the hind limbs also
popliteal LN, for MCTs on the cranial half of the thorax and front
limbs prescapular and axillary LNs, for MCTs of the neck mandibular
and prescapular LNs, for MCTs on the head both left and right man-
dibular LNs). Thoracic radiographs were available in the majority of
cases to assess intra-thoracic lymph nodes. Peripheral lymph nodes
were assessed on palpation, however, for axillary, inguinal and medial
iliac lymph nodes ultrasound was used. All lymph nodes assessed were
sampled where possible, however, axillary, inguinal and medial iliac
lymph nodes were difficult to sample when normal in size. Regional
lymphadenomegaly was documented in 33 dogs (40%). Sixty-one dogs
(74%) had at least one regional LN assessed cytologically (n = 55) and/
or histologically (n = 48). Overall 41 dogs (50%) were diagnosed with
metastasis (Table 5).
All dogs underwent US with FNA of the spleen, however, FNA of
the liver was not performed in 4 dogs because its location deep within
the cranial abdomen was not safely accessible despite sedation. Cytol-
ogy of the liver was non-diagnostic in 3 dogs while all splenic samples
were diagnostic. A median 2 samples were taken each from the liver
and spleen (range 1-4). Variable degrees of cellularity and
haemodilution were present, however, most slides were of diagnostic
quality except for one dog with three out of four smears non-
diagnostic and one other dog with two out of four smears non-diag-
nostic. No complications were documented following hepatic or
splenic aspiration. US abnormalities were detected in the spleen and
liver in 29 (35%) and 9 (11%) dogs, respectively (Table 6). Cytologic
evaluation of the liver and/or spleen was consistent with no metasta-
sis in 61 dogs (74%), early metastasis in 15 dogs (18%) and overt
metastasis in 6 dogs (7%). Seventeen dogs had hepatic metastasis
(15 early and 2 overt metastasis); 12 of which had a normal appearing
liver on US (11 early and 1 overt metastasis). Nine dogs had splenic
metastasis (3 early and 6 overt metastasis), 3 of which had dogs a nor-
mal spleen on US (1 early metastasis and 2 overt metastasis). LN
metastasis was present in 27 (44%) of the 61 dogs without metastasis
to the liver or spleen, in 9 (60%) of the 15 dogs with early metastasis
and in 5 (83%) of the 6 dogs with overt metastasis. Overall, 14 of the
21 dogs (67%) with visceral metastasis had regional LN metastasis.
Fourteen of the 41 dogs (34%) with LN metastasis had distant visceral
metastasis.
The sensitivity, specificity, PPV, and NPV for splenic US in
detecting metastasis were 67% (CI 0.30-0.93), 68% (CI 0.57-0.79),
21% (CI 0.08-0.4) and 94% (CI 0.84-0.99), respectively. Repeating
these calculations for dogs with overt splenic metastasis only as true
positives minimally affected these values. The sensitivity, specificity,
PPV, and NPV for liver US in detecting metastasis (only including dogs
with diagnostic liver cytology) were 29% (CI 0.10-0.56), 93%
(CI 0.83-0.98), 56% (CI 0.21-0.86) and 82% (CI 0.70-0.90), respec-
tively. If only dogs with overt metastasis were used as true positives,
the sensitivity, specificity, PPV and NPV were 50%, 89%, 13% and
98%, respectively.
Fifty dogs (61%) were considered to have received adequate local
therapy. Thirteen dogs (16%) received definitive RT (Table 7). Adju-
vant RT was not pursued in 6 of 7 dogs with narrow margins and
16 of 28 dogs with incomplete margins. Margin evaluation was not
available in two dogs. Fifty-three dogs (65%) received vinblastine-
prednisolone chemotherapy, with 38 dogs completing the protocol.
Sixty-six percent, 67%, and 50% of dogs without, with early, and with
overt visceral metastasis, respectively, received chemotherapy. Four
dogs (5%) received prednisolone alone.
The median TTP for dogs with no metastasis, early metastasis and
overt metastasis was not reached (observed range 50-811),
305 (42-465) and 69 (55-81) days, respectively (P < .001) (Figure 1).
The MST for dogs with no metastasis, early metastasis and overt
metastasis was not reached (observed range 50-813), 322 (18-553)
and 81 (68-183) days, respectively (P < .001) (Figure 2). Observed
median follow-up for the dogs was 597 days (range 66-1505 days). At
the time of writing, 38 dogs (54%) were still alive at last point of
follow-up, or censored due to death for a reason unrelated to MCT.
The nine censored dogs (11%) were euthanised for various reasons
including: vestibular syndrome, large cell lymphoma, intra-cranial
meningioma, acute gastro-enteritis, carotid body tumour, metastatic
melanoma, bone tumour, pyometra and degenerative myelopathy.
Three dogs in the early metastasis group (20%) were censored more
than 500 days following diagnosis; two of those dogs had adequate
local control and all three were treated with chemotherapy.
Forty-one dogs (50%) had repeat FNA of liver/spleen at least
once during a recheck visit following completion of treatment. Of the
21 dogs with visceral metastasis at initial staging, 9 dogs had repeat
FNA and only 4 had cytologic evidence of metastasis (one overt);
Eight of the nine dogs had received chemotherapy. Of the 61 dogs
without metastasis on initial staging, 32 dogs (52%) were reassessed.
TABLE 2 Breed distribution of the dogs with high-risk mast cell
tumours enrolled in the study




Staffordshire Bull Terrier 6
Pug 4
Shar-Pei 2











Native American Indian Dog 1
German Shepherd 1
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metastasis (n = 61)
Dogs with early
metastasis (n = 15)
Dogs with convincing
liver/spleen metastasis (n = 6)
Labradors (%) 37 (45) 24 (39) 9 (60) 4 (67)
M (%) 39 (48) 29 (47) 9 (60) 1 (17)
MN (%) 26 (32) 18 (30) 8 (53) 0 (0)
F (%) 43 (52) 32 (52) 6 (40) 5 (83)
FN (%) 33 (41) 26 (43) 3 (20) 4 (67)
Mean age (median) 7.57 (7.7) 7.16 (7.5) 8.46 (8.2) 9.55 (9.8)
Median weight (kg) 28.3 26.4 35.5 30.65
High risk location (%) 22 (27) 18 (30) 4 (27) 0 (0)
SC location (%) 12 (15) 7 (11) 3 (20) 2 (33)
Median size MCTs (cm) 2 2 3 4.3
Recurrent MCT (%) 10 (12) 4 (7) 5 (33) 1 (17)
Rapid growth/ulceration (%) 38 (46) 25 (41) 8 (53) 5 (83)
Systemic clinical signs (%) 2 (2) 1 (2) 0 (0) 1 (17)
Grade assessed (%) 64 (78) 53 (87) 8 (53) 3 (50)
P (%) 61 (74) 50 (82) 8 (53) 3 (50)
High (%) 25 (30) 19 (31) 4 (27) 2 (33)
K (%) 51 (62) 41 (67) 7 (47) 3 (50)
High (%) 26 (32) 20 (33) 3 (20) 3 (50)
High P or K (%) 34 (41) 27 (44) 4 (27) 3 (50)
MC analysed 69 (84) 55 (90) 11 (73) 3 (50)
High (%) 27 (33) 19 (31) 5 (15) 3 (50)
Previous MCTs (%) 13 (16) 7 (11) 3 (20) 3 (50)
Concurrent MCTs (%) 7 (9) 6 (10) 0 (0) 1 (17)
Median time from diagnosis to staging (days) 20 20 16 15
Abnormal CBC/BC (%) 43 (52) 28 (46) 10 (67) 5 (83)
LN assessed by cytology or histology (%) 61 (74) 43 (70) 13 (87) 5 (83)
Lymphadenomegaly 33 (40) 23 (38) 5 (33) 5 (83)
Metastatic LN (%) 41 (50) 27 (44) 9 (60) 5 (83)
Thoracic radiographs (%) 73 (89) 57 (93) 11 (73) 5 (83)
Abnormalities (%) 14 (17) 12 (20) 2 (13) 0 (0)
Abnormal hepatic US 9 (11) 4 (7) 4 (27) 1 (17)
Abnormal splenic US 29 (35) 18 (30) 7 (47) 4 (67)
Surgery (%) 73 (89) 58 (95) 12 (80) 3 (50)
Complete margins (%) 36 (44) 29 (48) 5 (33) 2 (33)
Definitive RT (47.5-48 Gy) 13 (16) 11 (18) 2 (13) 0 (0)
Palliative RT (25 Gy) 1 (2) 1 (2) 0 (0) 0 (0)
Adequate local control 50 (61) 41 (67) 7 (47) 2 (33)
Vinblastine/prednisolone 53 (65) 40 (66) 10 (67) 3 (50)
Progressive disease 31 (38) 16 (26) 9 (60) 6 (100)
Median TTP Not reached Not reached 305 69
Died (%) 38 (46) 24 (39) 9 (60) 5 (83)
Died due to MCT (%) 29 (35) 16 (26) 8 (53) 5 (83)
MST Not reached Not reached 322 81
Still alive (%) 44 (54) 37 (61) 6 (40) 1 (17)
Median follow-up (range) 597 (66-1505) 614 (92-1505) 457 (141-973) 66 (66)
Abbreviations: BC, serum biochemistry; CBC, complete blood count; F, female; K, Kiupel; LN, lymph node; MCT, mast cell tumour; M, male; MC, mitotic
count (high >5); MST, median survival time; N, neutered; P, Patnaik; SC, subcutaneous; RT, radiation therapy; TTP, time to progression; US, ultrasound.
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Two dogs developed early metastasis and two dogs developed overt
visceral metastasis. All dogs with metastasis at recheck were
euthanised within 6 months of detection of metastasis.
For the 12 dogs with subcutaneous MCTs risk factors included:
recurrence only (n = 1); LN metastasis only (n = 3); rapid growth and
ulceration (n = 2); high grade and high MC (n = 2); rapid growth and
ulceration with LN metastasis (n = 1); recurrence and high grade with
LN metastasis (n = 1); recurrence, rapid growth and ulceration with
LN metastasis (n = 1); recurrence, rapid growth and ulceration, high
MC and LN metastasis (n = 1). Grade was not available in seven dogs;
two dogs did not have surgery and the pathologist did not grade sub-
cutaneous tumours for the remaining five dogs. MC was provided in
all cases where surgery was performed. Five of those 12 dogs had evi-
dence of visceral metastasis (three early, two overt).
Seven dogs presented with concurrent MCTs, with only one dog
having visceral metastasis (overt). None of these concurrent tumours
demonstrated any negative prognostic factors. In the dog with visceral
metastasis the primary tumour had a high grade Kiupel MCT with a
high MC which led to inclusion in the study.
Twelve dogs had previously been diagnosed with other MCTs
prior to enrolling in the study. Five of those dogs had evidence of vis-
ceral metastasis (two of which overt metastasis). None of those previ-
ous MCT were associated with documented negative prognostic
indicators.
On univariable analysis (Table 8), rapid growth and ulceration,
Patnaik grade III, Kiupel high grade, high MC, liver or spleen metasta-
sis, surgical removal, and adequate local control were prognostic for
TTP. Univariables associated with MST included rapid growth and
ulceration, Patnaik grade III, Kiupel high grade, high MC, liver or
spleen metastasis and adequate local control. On multivariable analy-
sis (Table 9), within the primary tumour characteristics group, only
Patnaik grade III or Kiupel high grade was significantly associated with
TTP or MST (P = .02 and P = .04, respectively). Within the metastatic
group, both early visceral metastasis and overt metastasis were nega-
tively associated with TTP (P = .003 and P < .001, respectively) and
MST (P = .01 and P < .001, respectively). Of the treatment variables,
adequate local control was associated with both TTP (P = .001) and
MST (P = .01). As four dogs did not have liver FNA and three addi-
tional dogs had non-diagnostic liver samples, statistical analysis
assessing association between metastasis status and outcome was
repeated not including those seven dogs, and significant findings were
unchanged.
4 | DISCUSSION
As we hypothesized, US was a poor predictor of cytologic metastasis
of liver or spleen as previous literature has suggested,44,45 yet dogs
with early metastasis had improved outcome compared to those with
overt metastasis. Sensitivity of US was unacceptably low for both liver
and spleen, whereas specificity was high at 93% for hepatic appear-
ance. For both liver and spleen, NPVs were high, which may have
been influenced by the low prevalence of distant metastasis in our
population.
The consequences of being assigned as having visceral metastasis
are tremendous, as poor survival has been shown with MSTs ranging
from 34 to 110 days.27,44,61 It influences treatment options in our
institution, wherein palliative treatment is considered with more
weight compared to definitive treatments in cases of visceral metasta-
sis, given the poor outcome for dogs with overt metastasis. On the
other hand, dogs with false negative results may undergo intensive
treatment protocols involving chemotherapy and definitive RT with
TABLE 4 Number of dogs with visceral metastasis based on
anatomic categorisation of mast cell tumours for the 82 dogs









Cutaneous 48 9 4
Subcutaneous 7 3 2
Mucocutaneous 6 2 0
Visceral 0 1 (intestine) 0
TABLE 5 Characteristics of lymph nodes assessed in 82 dogs
n
Dogs with at least one enlarged ln 33
Enlarged lns 45
Dogs with at least one ln assessed on cytology 55
Lns assessed on cytology 99
Dogs with ln mets on cytology 32
Lns positive for mets on cytology 43
Dogs with at least one ln assessed on histopathology 48
Lns assessed on histopathology 72
Dogs with ln mets on histopathology 34





Dogs with lns assessed on cytology and/or histopathology 61
Dogs with metastatic lns on cytology and/or histopathology 41
Dogs with lns assessed on cytology and histopathology 41
Dogs with metastasic lns on cytology and histopathology 23
Dogs with non-metastastic lns on cytology and histopathology 13
Dogs with discordant ln results between cytology and
histopathologyb
4
Abbreviations: ln, lymph node; mets, metastasis.
aLn metastasis status according to previously published classification.32
bAt least one ln negative on cytology, but positive for metastasis on
histopathology.
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associated toxicities rather than palliative treatments focused on
improving or maintaining quality of life. Considering these conse-
quences, assigning cases to a stage based on US findings alone or
aspirating liver and spleen only when sonographically abnormal may
not be justified.
As full abdominal US is time-consuming and often contributes to
the cost, where finances could be preserved for the pursuit of treat-
ment, it is important to ensure that this technique in dogs with high-
risk MCTs is defensible. A brief US to assess any regional lymph nodes
that are difficult or cannot be palpated (non-peripheral) and to guide
US-guided sampling of the liver and spleen may be more useful. Com-
prehensive abdominal US could still be considered to rule out concur-
rent disease; however, this could be reserved for dogs with systemic
signs, where concurrent disease is likely or would influence therapeu-
tic options, or for owners wishing to pursue complete imaging. Of
note, similar findings were recently reported for dogs undergoing
abdominal CT for MCT staging, in which cytologic findings did not
correlate well to CT changes and sampling was recommended in the
absence of abnormal CT findings.62
Early visceral metastasis was significantly associated with out-
come and dogs with early visceral metastasis have the potential for
long-term control. As it can be difficult to differentiate neoplastic
from reactive mast cells, the relevance of mildly increased numbers of
TABLE 6 Ultrasonographic findings in liver and spleen in dogs with high-risk mast cell tumours and corresponding aspiration cytology results
when evaluated for metastasis. Numbers represent absolute numbers of dogs with each characteristic while numbers in parenthesis represent
percentage of dogs with the denominator represented at the top of each table
Spleen
All
dogs (n = 82)
Dogs without
metastasis (n = 74)
Early
metastasis (n = 3)
Overt
metastasis (n = 6)
Single nodule (%) 6 (7) 3 (4) 2 (67) 1 (17)
Splenic mass (%) 2 (2) 1 (1) 0 (0) 1 (17)
Multiple nodules (%) 10 (12) 8 (11) 0 (0) 2 (33)
Diffusely altered echogenicity
(%)
14 (17) 12 (16) 0 (0) 2 (33)
Splenomegaly (%) 5 (6) 5 (7) 0 (0) 0 (0)
Multiple abnormalities (%) 7 (9) 6 (8) 0 (0) 2 (33)









Single nodule (%) 2 (3) 0 (0) 2 (13) 0 (0)
Multiple nodules (%) 4 (5) 1 (2) 2 (13) 1 (50)
Diffusely altered echogenicity
(%)
4 (5) 1 (2) 2 (13) 1 (50)
Hepatomegaly (%) 2 (3) 1 (2) 1 (7) 0 (0)
Multiple abnormalities (%) 3 (4) 0 (0) 2 (13) 1 (50)
Normal (%) 67 (88) 55 (74) 11 (73) 1 (50)
TABLE 7 Summary of treatment for the 13 dogs receiving
definitive radiation therapy
RT Dogs (n)
RT following incomplete excision 12
RT following narrow excision 1
RT protocol 16 × 3 Gy 12
RT protocol 19 × 2.5 Gy 1
LN bed irradiated following excision of metastatic LN 10
LN irradiated prophylactically 1
Manual planning 10
CT-guided RT planning 3
Abbreviations: CT, computed tomography; LN, lymph node; RT, radiation
therapy. F IGURE 1 Kaplan-Meier curves showing time to progression
(TTP) for dogs with no metastasis (n = 61), early metastasis (n = 15)
and overt metastasis (n = 6) with median TTP not reached, 305 and
68 days, respectively (P < .001)
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mast cells in the liver and/or spleen was questionable, especially given
the range of survival in this small group. It is possible that biopsies
may provide meaningful information to clarify the likelihood of metas-
tasis; however, this adds a layer of risk to the dog and is not standard
practice. Alternatively, additional work needs to be done to improve
detection of neoplastic vs reactive mast cells; IHC (eg, CD25) and/or
molecular testing (eg, c-kit mutational status) may have promise if vali-
dated in the dog as reliable markers.63-65 Because an association with
outcome was detected in our population, it suggests that in dogs with
high-risk MCTs, at least a proportion of dogs have metastatic mast
cells. This is further supported by the fact that at least four dogs with
early metastasis continued to have cytologic evidence of metastasis
on restaging. Despite the inferior outcome for dogs with early metas-
tasis compared to dogs without distant metastasis, the median TTP
was 305 days with a range of up to 973 days. This data justifies the
pursuit of definitive treatment with adequate local control and che-
motherapy when early metastasis is identified. It is possible that the
dogs with extended survival had increased non-metastatic mast cells
in the spleen and liver, especially given that five dogs with early
metastasis had no evidence of mast cell disease on restaging. Alterna-
tively they may have enjoyed a favourable response to chemotherapy
because had fewer metastatic mast cells or if they had mast cells more
responsive to chemotherapy, however, the use of chemotherapy in
this group of dogs with high-risk MCTs was not associated with
improved outcome.
The MST for dogs with overt metastasis was 81 days (compared
to 322 days for dogs with early metastasis and > 614 days for the
dogs without visceral metastasis). This is similar to what has previ-
ously been reported in literature, with survival ranges of 34-119 days
reported.27,44,61 The majority of cases mentioned in the literature
above had received systemic treatment, similar to the 62% of dogs in
our study that received chemotherapy.
Of the primary tumour characteristics, metastasis and treatment
variables, only the presence of grade III or high grade Kiupel, early
metastasis, overt metastasis and adequate local control were signifi-
cantly associated with both TTP and MST on multivariable analysis. It
is important to highlight that this study was not designed to perform
robust multivariable statistical analysis and in order to evaluate a num-
ber of prognostic factors, we would need 10 times as many events as
prognostic variables to detect statistical significance.66 Even with
comprehensive multivariable analysis on large case numbers, it is chal-
lenging to interpret the results as there is a complex relationship
between primary tumour characteristics, metastatic status and treat-
ment variables. For example, dogs with overt visceral metastasis
achieved adequate local control less commonly (33% vs 67% of the
dogs without metastasis). This is possibly due to more aggressive bio-
logic behaviour, however, this cannot be concluded with certainty as
definitive treatment options are less likely to be pursued in the face of
visceral metastasis. However, the study was designed to clearly define
“increased numbers of mast cells” and to follow dogs with high-risk
F IGURE 2 Kaplan-Meier curves showing survival times for dogs
with no metastasis (n = 61), early metastasis (n = 15) and overt
metastasis (n = 6). For dogs without metastasis, the median survival
time (MST) was not reached, while for dogs with early and overt
visceral metastasis, the MST was 322 and 81 days, respectively
(P < .001). The full, striped and dotted curves represent dogs without
metastasis, with early metastasis and overt visceral metastasis,
respectively
TABLE 8 Univariable analysis for multiple variables evaluating association with time to progression (TTP) and median survival time (MST);
Likelihood ratio test with P < .05 considered significant (indicated by *)
Prognostic variables TTP analysis Hazard ratio MST analysis Hazard ratio
Growth and ulceration P < .001* 1.34 P < .001* 1.87
High-risk location P = .6 1.12 P = .5 0.14
Recurrence P = .1 0.49 P = .2 0.71
Lymph node metastasis P = .1 0.55 P = .07 0.71
Grade III (Patnaik) P < .001* 4.38 P < .001* 6.3
High grade (Kiupel) P = .001* 1.70 P = .001* 2.11
Mitotic index >5 P < .001* 1.80 P < .001* 1.84
Visceral metastasis P < .001* 5.27 P < .001* 4.60
Vinblastine/prednisolone chemotherapy P = .5 1.11 P = .4 1.38
Surgery P = .04* 2.86 P = .1 2.38
Adequate local control P < .001* 3.91 P = .003* 3.49
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tumours to evaluate if definitive treatment is rational in dogs with
early visceral metastasis.
As aspiration of the liver and spleen were previously demon-
strated to be safe with no obvious complications27,44; repeat imaging
was not routinely performed the same day following sampling to rule
out intra-abdominal haemorrhage. No complications were seen in this
study.
Fifty percent of the dogs with high risk MCTs had LN metastasis,
18% had early liver and/or spleen metastasis and 7% had overt metas-
tasis. The LN metastatic rate in this study was high, which reflects the
population of high-risk MCTs recruited for this study as was seen in
previous literature.12,30,39,43 The rate could have been biased as LN
metastasis was one of the inclusion criteria. Early metastasis to the
liver and/or spleen has not been previously associated to outcome to
the authors' knowledge, and the rate of early metastasis using our
criteria was higher than expected at 18%. Variable rates of distant vis-
ceral metastasis at time of diagnosis have been reported in previous
publications, ranging from 0% to 19%, but studies utilized different
inclusion criteria and cytologic evaluation of liver and/or spleen was
not always performed.1,18,21,27,28,39,40,42,50,67,68 Combining both early
and overt liver/spleen metastatic rates in this study, 25% of dogs had
distant metastasis, supporting the routine use of hepatic and splenic
cytology in the staging of dogs with high risk MCTs.
LN metastasis was not significantly associated with outcome in
this study. This does not definitively mean that it is not prognostic in
the population overall, as the inclusion criteria were designed to
include dogs with at least one negative prognostic factor. Whether LN
metastasis is always a negative prognostic indicator is controversial as
multiple studies show a negative impact on outcome11,12,18,39; how-
ever, other publications show that if treated appropriately a meta-
static LN does not necessarily implicate a worse prognosis.36,43,69
Seven percent of dogs had overt distant metastasis with five of the
six dogs having concurrent LN metastasis. Of the 15 dogs with early
visceral metastasis, 47% did not have LN metastasis in the majority of
LNs assessed on cytology and/or histopathology. Based on literature
of sentinel LNs, those assessed might not have been the draining
LNs.70 Despite the lack of sentinel lymph node mapping in this study,
multiple regional lymph nodes, all considered to be probable draining
lymph nodes based on anatomic knowledge, were assessed in all cases
with aspirates obtained wherever possible. Seventy-four percent of
dogs had at least one LN sampled. Localisation and excision of normal
sized axillary and inguinal lymph nodes can be challenging and it was
not routine practice to prescribe thoracoscopic surgery, thoracotomy,
or exploratory laparotomy to remove normal sized sternal and medial
iliac lymph nodes. As sentinel lymph node mapping was not per-
formed and not all dogs had lymph nodes assessed on cytology and/or
histopathology, it is likely that the lymph node metastatic rate was
underestimated.70,71 Dogs that did not have lymph nodes sampled
were excluded for statistical analysis when assessing for association
between LN metastatic status and outcome. Based on a recent study,
there may be value in either removing regional lymph nodes at risk for
metastasis or prophylactically treating them in dogs considered at
high-risk for metastasis.69,72 Sentinel LN mapping may therefore play
a prominent role in determining more locally invasive procedures to
remove additional tissue.73 Visceral metastasis without a detectable
metastasis to LNs has been reported in previous literature; therefore,
not having a metastatic LN does not completely remove the need to
assess liver/spleen for metastasis.27,28,44-52,55,60,61
Seven dogs lacked diagnostic liver cytology, therefore additional
analysis was performed to exclude these dogs, which did not alter our
findings. This study demonstrates that in most (but not all) dogs, liver
samples can be taken safely with sedation and that few cytologic sam-
ples may be non-diagnostic. Repeat aspiration of the liver was offered
to all clients prior to treatment for complete staging if non-diagnostic
samples were obtained; however, repeat sampling was declined. In
the author's opinion an attempt at cytology of liver should always be
made based on the low sensitivity of ultrasound, however, considering
the high NPV, it may be reasonable to assume that liver is negative
TABLE 9 Multivariable analysis for
prognostic variables evaluating
association with time to progression
(TTP) and median survival time (MST);
Likelihood ratio test with P < .05
considered significant (indicated by *)
Prognostic variables TTP analysis Hazard ratio MST analysis Hazard ratio
Primary tumour
High grade P and/or K 0.02* 4.9 0.04* 4.3
Growth and ulceration 0.10 2.45 0.06 3.03
Recurrence 0.38 2.00 0.26 2.49
High risk location 0.26 2.00 0.26 1.98
Metastasis status
LN mets 0.75 1.13 0.36 1.45
Early mets 0.003* 3.58 0.01* 2.92
Overt mets <0.001* 29.37 <0.001* 10.69
Treatment
Surgery 0.66 0.81 0.79 0.87
VBL 0.38 1.42 0.93 1.03
Adequate local control 0.001* 0.21 0.01* 0.34
Abbreviations: K, Kiupel; LN, lymph node; mets, metastasis; P, Patnaik; VBL vinblastine.
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for metastasis rather than positive when determining the
therapeutic plan.
Adequate local control was defined at the start of the study, rec-
ognizing that there is no clear standard of what defines loco-regional
radiation therapy boundaries or exactly what margin is required to
control grade 3 MCTs.56 However we were consistent with current
literature in the standards set forth at the start of the study.53,56,72
Labradors were overrepresented at 45% of the canine population
in this study. This is markedly higher than multiple previous reports
that included 11%-27% Labradors.11,12,19,28,30,31,34,35,37,39,41,74 In two
studies that used similar inclusion criteria to ours, Labradors represen-
ted 41% and 37% of their study populations, supporting the possibility
that Labradors are not only more prone to developing MCTs but are
also more likely to develop high-risk MCTs.18,44 A recent study did
not identify the Labrador Retriever as a breed with an increased risk
of developing higher grade MCTs, however, the study did not take
other prognostic variables into consideration.75 Epidemiologic studies
would be required to evaluate the proportion of Labradors in the
overall population in this region and in our referral hospital prior to
drawing any conclusions.
Only dogs with high-risk MCTs that fit to our specific criteria
were included in the study. It is possible that some dogs were not
included in the study even though they had negative prognostic fac-
tors that we were unaware of, particularly as we did not have tumour
size for all dogs if they were referred following treatment at the refer-
ring practice.61 Size has previously been reported as prognostic for
dogs with MCTs, however, was not evaluated as a prognostic indica-
tor in this study as recent rapid growth was more easily assessed,
even in cases that sought initial surgery with the referring practice.61
Size was not consistently recorded for cases which did not initially
seek treatment with oncology, and as MCTs can shift size dramati-
cally, we felt that recent rapid growth was more reliable. Additionally,
others have suggested that rapid growth rather than size might be a
more accurate predictor of prognosis.8 Additional studies could also
include size, to better determine if it is an independent negative
factor.19,21,28,56
It is currently difficult to conclude a true visceral metastasis rate
in low-risk MCTs (defined as MCTs lacking negative prognostic indica-
tors as used in the current study) as previous literature did not consis-
tently clarify all negative factors nor report consistent hepatic or
splenic aspiration cytology.12,28,31,35,40,41,76 In multiple studies
assessing metastasis in different grade MCTs, all dogs with visceral
metastasis had at least one negative prognostic factor.38,44,53,61 A
separate study is needed to clearly identify the risk of visceral metas-
tasis in low-risk dogs, or dogs lacking the high-risk features defined
here or in other literature.
Even though previous literature is suggestive that subcutaneous
MCTs are less biologically aggressive77,78; 12 dogs with subcutaneous
tumours were included in our study based on our negative prognostic
factor requirement for inclusion. Indeed, 42% of these dogs demon-
strated evidence of visceral metastasis. This suggests that dogs with
subcutaneous MCTs that present with negative prognostic factors
benefit from full staging including cytology of the liver and spleen.
Dogs with a history of previous MCTs or concurrent MCTs did
not demonstrate any negative prognostic factors for those tumours.
Of the dogs with previous MCTs 42% had visceral metastasis. Of the
dogs with concurrent MCTs, only 14% had visceral metastasis. Based
on previous literature it is clear that dogs that develop a MCT are at
risk of developing more MCTs in the future and it has been suggested
that these are most likely de novo tumours rather than cutaneous
metastasis.19,21,29 The authors used an arbitrary 14-day duration and
a requirement for five new MCTs to differentiate de novo tumour
from metastasis; however, true differentiation is unlikely this simple
and molecular testing to identify specific mutations (eg, c-kit) may pro-
vide more definitive information.63,79 As the dogs with previous MCTs
that were included in this study did not have any negative prognostic
indicators at the time, we considered the new MCT requiring referral
to be de novo. In the dog with multifocal MCTs with overt visceral
metastasis at time of diagnosis, the authors considered the abundance
of lesions most likely representative of mast cell metastasis, but we
cannot rule out that these all represented de novo tumours. This dog
developed progressive cutaneous MCTs despite chemotherapy with a
TTP of 65 days.
One limitation is that multiple diagnostic imagers, anatomic
pathologists and clinical pathologists were involved in this study and
not all samples were reviewed by the same individuals. Grading was
not available for all cases and second opinion histopathology was not
possible for this study. While we contend that our data is reflective of
clinical practice, where multiple pathologists may be responsible for
interpreting cases, the study could have be strengthened if assess-
ment was standardized, particularly to evaluate for agreement in the
designation of “early” metastasis, and for determination of post-sur-
gery, formalin-fixed tumour diameter. Another limitation was that not
all dogs were initially evaluated by the specialty service and negative
prognostic factors may have been unreported by the owner or refer-
ring veterinarian. While we chose to be strict in our inclusion criteria
for high risk, it is likely that our criteria was not all encompassing and
may have missed some eligible cases.
5 | CONCLUSION
US findings to detect liver and spleen metastasis is poorly indicative
of metastasis, even when only dogs defined as high-risk for visceral
metastasis were evaluated. US-guided FNA of the liver and spleen
should be performed in all high-risk MCTs, regardless of the US
appearance or the regional LN status. The routine use of complete US
is questionable unless there are clinical signs or concurrent disease
suspected. In this group of 82 dogs considered high-risk for MCT
metastasis, 18% of dogs had cytologic evidence of early metastasis,
while 7% had cytologic evidence of overt metastasis to liver and/or
spleen. Dogs with early metastasis had improved TTP and MST com-
pared to dogs with overt metastasis, and 20% of dogs in the early
metastasis group experienced survival times >500 days. Additional
study is required to understand the complex relationship between
multiple prognostic variables and the presence of early visceral
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metastasis, as well as to investigate methods to more definitively dif-
ferentiate metastatic from reactive mast cells.
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